PriceTargets.com logo

Zomedica Pharmaceuticals Corp. (ZOM.V) - ZOM Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.29 As of 02/6/2020 12:59 AM ET
▼ -0.02 (-6.56%)

This chart shows the closing price for ZOM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zomedica Pharmaceuticals Corp. (ZOM.V) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZOM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZOM

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Zomedica Pharmaceuticals Corp. (ZOM.V) in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.29.

This chart shows the closing price for ZOM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Zomedica Pharmaceuticals Corp. (ZOM.V). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/5/2019HC WainwrightReiterated RatingBuy
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Zomedica Pharmaceuticals Corp. (ZOM.V) logo
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Read More

Today's Range

Now: C$0.29
Low: C$0.29
High: C$0.29

50 Day Range

MA: C$0.29
Low: C$0.29
High: C$0.29

52 Week Range

Now: C$0.29
Low: C$0.29
High: C$1.50

Volume

4,800 shs

Average Volume

2,858 shs

Market Capitalization

C$36.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Zomedica Pharmaceuticals Corp. (ZOM.V)?

The following Wall Street research analysts have issued stock ratings on Zomedica Pharmaceuticals Corp. (ZOM.V) in the last year:
View the latest analyst ratings for ZOM.

What is the current price target for Zomedica Pharmaceuticals Corp. (ZOM.V)?

0 Wall Street analysts have set twelve-month price targets for Zomedica Pharmaceuticals Corp. (ZOM.V) in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Zomedica Pharmaceuticals Corp. (ZOM.V) in the next year.
View the latest price targets for ZOM.

What is the current consensus analyst rating for Zomedica Pharmaceuticals Corp. (ZOM.V)?

Zomedica Pharmaceuticals Corp. (ZOM.V) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ZOM.

What other companies compete with Zomedica Pharmaceuticals Corp. (ZOM.V)?

Other companies that are similar to Zomedica Pharmaceuticals Corp. (ZOM.V) include Viridium Pacific Group, InMed Pharmaceuticals, Meta Growth, Charlotte's Web and MediPharm Labs. Learn More about companies similar to Zomedica Pharmaceuticals Corp. (ZOM.V).

How do I contact Zomedica Pharmaceuticals Corp. (ZOM.V)'s investor relations team?

The company's listed phone number is 734-369-2555. The official website for Zomedica Pharmaceuticals Corp. (ZOM.V) is www.zomedica.com. Learn More about contacing Zomedica Pharmaceuticals Corp. (ZOM.V) investor relations.